Clinical Trials
Imviva is committed to developing investigational allogeneic CAR-T cell therapies with the potential to address unmet needs for patients.
Advancing allogeneic CAR-T research — driven by our dedication to patients.
Ongoing Clinical Trials
RECRUITING
TENACITY-01
Frequently Asked Questions
-
What is a clinical trial?
A clinical trial is a study that helps researchers understand more about the safety and effectiveness of investigational treatments and is an essential part of developing new medicines.
-
What is CAR-T cell therapy?
CAR-T cell therapy is a type of immunotherapy (a treatment that works with the immune system). This approach uses T cells engineered with chimeric antigen receptors (CARs) to help them recognize and attack certain cells associated with disease.
-
What is allogeneic CAR-T cell therapy?
Allogeneic CAR-T cell therapy is an investigational approach that uses T cells from healthy donors. These therapies are manufactured in advance, which allows them to be more readily available for treatment.
Another type of CAR-T cell therapy is autologous CAR-T cell therapy. These therapies are made individually for each patient using T cells from their own body and may take several weeks to be prepared.
Allogeneic CAR-T cell therapies are still being studied in clinical trials, and their safety and effectiveness have not been established.
-
Expanded Access Policy
Read our expanded access policy here